Equine Laminitis- gaining footholds in a complex disease: a review of pathophysiology, current experimental models, and future therapeutic interventions.

摘要

Lanninitis is an important cause of lameness, morbidity, and mortality in horses, and is economically costly to the equine industry. A 1998 USDA survey of 1178 non-racetrack horse operations, including over 28,000 horses representing 28 states and approximately 83.9% of non-racehorses in the US, estimated laminitis to account for 7.5-15.7% of lameness problems with death or euthanasia resulting from laminitis in 4.7% of these horses.However, the estimated frequency of disease occurrence as reported in the literature varies from 1.5-34%, depending on underlying etiology or horse populations. A recently published cohort study of equine laminitis in Great Britain (2009-2011) estimates the prevalence of veterinary-diagnosed active laminitis to be 0.47%(approximately 1 in 200 horses seen by veterinarians). In comparison, a retrospective study performed at a tertiary care facility investigating the factors associated with non-survival in horses treated for laminitis from 1986-2003 reports 247 out of 591horses hospitalized for laminitis died or were euthanized, and that the severity of lameness was the most significant prognostic indicator, not the presence of systemic inflammatory diseases (e.g. phlebitis/thrombophlebitis, pneumonia, or treatment with NSAIDs).